INTEGURX THERAPEUTICS LLC

Medtech · Still private

Transdermal patch delivering ondansetron for pregnancy-induced nausea and vomiting

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$333K
Federal grants
$333K
1 award · 2024
Rank in peer group#347 of 445
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
7 pending · first 2015
Rank in peer group#88 of 445

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $333K$333K
2024FEDERAL ↑EQUITY ↓Cumulative $333K$333K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of an Ondansetron Transdermal Patch for Pregnancy-Induced Nausea and Vomiting$333K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 445 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#88 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 9
  • PendingTransdermal Anticoagulant CompositionsUSPTOApplication 18997356
  • PendingChemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsUSPTOApplication 17402807
  • PendingChemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsUSPTOApplication 16716857
Show all 9 patent records
  • Transdermal Anticoagulant CompositionsOct 30, 2025 · Application 18997356Pending
  • Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsApr 7, 2022 · Application 17402807Pending
  • Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsApr 23, 2020 · Application 16716857Pending
  • Abuse Deterrent Opioid Agonist Transdermal Compositions And Methods For Their UseFeb 20, 2018 · US 9,895,384Granted
  • Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsJan 7, 2016 · Application 14858097Pending
  • Chemical Compositions For Enhancing Transdermal Delivery Of Therapeutic AgentsNov 17, 2015 · US 9,186,352Granted
  • Transdermal Anticoagulant CompositionsApplication 63391127Pending
  • Transdermal Anticoagulant CompositionsApplication PCTUS2023070712Pending
  • Chemical Compositions And Methods For Enhancing Transdermal Delivery Of Therapeutic AgentsApplication PCTUS2013056391Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .